Keytruda and Lenvima Combination Shows Mixed Results in Gastroesophageal Cancer Trial

Clinical Trial Results:
The Phase III LEAP-015 trial of Keytruda (pembrolizumab) combined with Lenvima (lenvatinib) for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma showed mixed results134.

Primary Endpoints:
The trial met one primary endpoint by demonstrating a statistically significant improvement in progression-free survival (PFS) but failed to meet the other primary endpoint of overall survival (OS)134.

Secondary Endpoint:
The combination therapy also met a secondary endpoint by showing an improvement in objective response rate (ORR) compared to chemotherapy134.

Drug Background:
Keytruda is an anti-PD-1 monoclonal antibody, and Lenvima is a tyrosine kinase inhibitor (TKI). Both drugs are approved for various cancer types and are being studied in combination for other indications13.

Future Analysis:
Full results and analysis from the trial are expected to be presented at an upcoming medical meeting134.

Sources:

1. https://www.clinicaltrialsarena.com/news/msd-and-eisais-leap-gastroesophageal-cancer-trial-sees-mixed-success/

3. https://www.biospace.com/drug-development/mercks-keytruda-combo-fails-to-extend-survival-in-phase-iii-gi-cancer

4. https://www.empr.com/news/mixed-results-for-pembrolizumab-lenvatinib-in-advanced-gastroesophageal-cancer-trial/